rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MBRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
      Nov 16Yahoo FinanceMBRX
      Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
      Nov 4Yahoo FinanceMBRX
      Moleculin Biotech completes enrollment in AML trial phase
      Oct 20Investing.comMBRX
      Moleculin Biotech announces 1-for-20 reverse stock split
      Oct 16Investing.comMBRX
      Moleculin Announces Reverse Stock Split
      Oct 16Yahoo FinanceMBRX
      Moleculin Biotech Shareholders Approve Key Annual Meeting Actions

      Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailMBRX
      Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

      HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows: Session: Advances in Oncology PanelPresenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ETLocation: NYY Room at the Hard Rock Hotel NYC Mr. Klemp will discuss Mole

      Oct 7Yahoo FinanceMBRX
      Moleculin completes enrollment in Annamycin AML trial Part A
      Sep 29Investing.comMBRX
      Moleculin receives Mexican patent for Annamycin formulation
      Sep 23Investing.comMBRX
      Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

      Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposom

      Sep 23Yahoo FinanceMBRX
      Moleculin Biotech Faces Nasdaq Delisting Risk After Notice

      Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailMBRX
      Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation
      Sep 18Investing.comMBRX
      Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

      Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer

      Sep 14Yahoo FinanceMBRX
      Moleculin Biotech at H.C. Wainwright conference: aml hope builds
      Sep 11Investing.comMBRX
      Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
      Sep 11Yahoo FinanceMBRX
      Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

      - Video webcast now available here HOUSTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it participated in the Virtual Investor “Why Now” on-demand conference. During the presentation, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, highlighted the Company's clinical progress and long-term opportunity, discussing encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annam

      Aug 27Yahoo FinanceMBRX
      Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

      Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

      Aug 24Yahoo FinanceMBRX

      This is the newest page. Registered accounts read further back.